rosiglitazone has been researched along with Ureteral Obstruction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Averbukh, Z; Berman, S; Chachashvili, A; Cohen, N; Efrati, S; Siman-Tov, Y; Weissgarten, J | 1 |
| Gu, Y; Lin, Q; Lin, SY; Ma, J | 1 |
2 other study(ies) available for rosiglitazone and Ureteral Obstruction
| Article | Year |
|---|---|
Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Immunohistochemistry; Interleukin-10; Interleukin-4; Interleukin-6; Kidney; Male; Nitric Oxide; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta; Ureteral Obstruction | 2009 |
[Protection of rosiglitazone against renal interstitial lesion and its mechanism].
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Hypoglycemic Agents; Male; Nephritis, Interstitial; Nephrosclerosis; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta; Ureteral Obstruction | 2005 |